Valeant has another asset sale in the works

Valeant Pharmaceuticals may sell its eye surgery equipment business, according to Dow Jones.

Talks are still in their preliminary stages, but the business could sell for as much as $2.5 billion.

On Tuesday the company announced that it is in talks to sell one of its core businesses, Salix, to Takeda for $10 billion.

The beleaguered company is trying to sell assets to bring down its over $30 billion in debt.

More on this to come...